SCHEMBL377981 — predicted protein targets

Predicted protein targets (top 18)

	gene	UniProt	supporting neighbours	confidence
▸	MEN1	O00255	2/20	0.52

▸	KMT2A	Q03164	2/20	0.52

▸	HTT	P42858	3/20	0.48

▸	HPGD	P15428	4/20	0.48

▸	ALDH1A1	P00352	7/20	0.46

▸	POLB	P06746	1/20	0.46

▸	GAA	P10253	1/20	0.46

▸	SMN1; SMN2	Q16637	1/20	0.46

▸	MAPT	P10636	1/20	0.46

▸	CYP2C9	P11712	1/20	0.46

▸	TDP1	Q9NUW8	2/20	0.46

▸	RECQL	P46063	1/20	0.46

▸	HSP90AA1	P07900	1/20	0.46

▸	CACNA1B	Q00975	1/20	0.46

▸	APBA1	Q02410	1/20	0.46

▸	NPSR1	Q6W5P4	1/20	0.46

▸	FDFT1	P37268	1/20	0.45

▸	TSHR	P16473	2/20	0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL7464853	0.86	MEN1 (0.46)	MEN1KMT2AHTTHPGDALDH1A1
SCHEMBL6500593	0.86	ATM (0.51)	KMT2AALDH1A1SMN1; SMN2MAPT
SCHEMBL378276	0.84	TDP1 (0.60)	MEN1KMT2AHTTHPGDALDH1A1
SCHEMBL21997950	0.83	USP2 (0.61)	ALDH1A1POLBMAPTCYP2C9
SCHEMBL3457437	0.81	HPGD (0.55)	MEN1KMT2AHTTHPGDALDH1A1
SCHEMBL24754433	0.81	MEN1 (0.48)	MEN1KMT2AHTTHPGDALDH1A1
SCHEMBL7313812	0.81	ALDH1A1 (0.50)	MEN1KMT2AHTTHPGDALDH1A1
SCHEMBL7323856	0.81	ALDH1A1 (0.50)	MEN1KMT2AHTTHPGDALDH1A1
SCHEMBL20188098	0.81	HPGD (0.65)	MEN1KMT2AHTTHPGDALDH1A1
SCHEMBL22015905	0.81	HPGD (0.65)	MEN1KMT2AHTTHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-3886904-B1	IRAK DEGRADERS AND USES THEREOF	KYMERA THERAPEUTICS INC (US)	2026-04-22	—	—	EP	disclosed
US-20250163042-A1	IRAK DEGRADERS AND USES THEREOF	KYMERA THERAPEUTICS, INC.	2025-05-22	—	—	US	disclosed
US-12258341-B2	IRAK degraders and uses thereof	KYMERA THERAPEUTICS, INC. (US)	2025-03-25	—	—	US	disclosed
EP-2408454-B1	NOVEL ANTI-INFLAMMATORY AGENTS	RESVERLOGIX CORP (CA)	2024-07-24	—	—	EP	disclosed
US-20240239777-A1	IRAK DEGRADERS AND USES THEREOF	KYMERA THERAPEUTICS, INC.	2024-07-18	—	—	US	disclosed
US-11807636-B2	IRAK degraders and uses thereof	KYMERA THERAPEUTICS, INC. (US)	2023-11-07	—	—	US	disclosed
US-20220324854-A1	IRAK DEGRADERS AND USES THEREOF	KYMERA THERAPEUTICS, INC.	2022-10-13	—	—	US	disclosed
US-11407719-B2	Anti-inflammatory agents	RESVERLOGIX CORP. (CA)	2022-08-09	—	—	US	disclosed
US-11352350-B2	IRAK degraders and uses thereof	KYMERA THERAPEUTICS, INC. (US)	2022-06-07	—	—	US	disclosed
US-11352350-B2	IRAK degraders and uses thereof	KYMERA THERAPEUTICS, INC. (US)	2022-06-07	—	—	US	disclosed
WO-2020113233-A1	IRAK DEGRADERS AND USES THEREOF	KYMERA THERAPEUTICS, INC. (US)	2020-06-04	—	—	WO	disclosed
US-20190119222-A1	NOVEL ANTI-INFLAMMATORY AGENTS	RESVERLOGIX CORP. (CA)	2019-04-25	—	—	US	disclosed
US-10131640-B2	Anti-inflammatory agents	RESVERLOGIX CORP. (CA)	2018-11-20	—	—	US	disclosed
US-20160137613-A1	NOVEL ANTI-INFLAMMATORY AGENTS	RESVERLOGIX CORP. (CA)	2016-05-19	—	—	US	disclosed
US-9238640-B2	Anti-inflammatory agents	RESVERLOGIX CORP. (CA)	2016-01-19	—	—	US	disclosed
WO-2013175281-A1	USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) PROTEINS	RVX THERAPEUTICS INC. (CA)	2013-11-28	—	—	WO	disclosed
US-20130281399-A1	TREATMENT OF DISEASES BY EPIGENETIC REGULATION	RVX THERAPEUTICS INC. (CA)	2013-10-24	—	—	US	disclosed
US-20120040954-A1	NOVEL ANTI-INFLAMMATORY AGENTS	HEPALINK (HONG KONG) LIMITED (HK)	2012-02-16	—	—	US	disclosed
EP-2408454-A2	NOVEL ANTI-INFLAMMATORY AGENTS	RESVERLOGIX CORP. (CA)	2012-01-25	—	—	EP	disclosed
WO-2010106436-A2	NOVEL ANTI-INFLAMMATORY AGENTS	RESVERLOGIX CORP. (CA)	2010-09-23	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-11407719-B2	Anti-inflammatory agents	VCAM1, ICAM1, IL6	MEN1 3826/4885KMT2A 4037/4885HTT 4509/4885
US-12258341-B2	IRAK degraders and uses thereof	IRAK2, IRAK3, IRAK1	MEN1 4055/4885KMT2A 445/4885HTT 2464/4885
US-20160137613-A1	NOVEL ANTI-INFLAMMATORY AGENTS	VCAM1, ICAM1, IL6	MEN1 3913/4885KMT2A 3826/4885HTT 4528/4885
US-20130281399-A1	TREATMENT OF DISEASES BY EPIGENETIC REGULATION	PHKB, BAZ2A, EP300	MEN1 4236/4885KMT2A 199/4885HTT 663/4885
US-20250163042-A1	IRAK DEGRADERS AND USES THEREOF	IRAK2, IRAK3, IRAK1	MEN1 4055/4885KMT2A 445/4885HTT 2464/4885
US-10131640-B2	Anti-inflammatory agents	VCAM1, ICAM1, IL6	MEN1 3826/4885KMT2A 4037/4885HTT 4509/4885
US-11352350-B2	IRAK degraders and uses thereof	IRAK2, IRAK3, IRAK1	MEN1 4055/4885KMT2A 445/4885HTT 2464/4885
US-20220324854-A1	IRAK DEGRADERS AND USES THEREOF	IRAK2, IRAK3, IRAK1	MEN1 4055/4885KMT2A 445/4885HTT 2464/4885
US-20240239777-A1	IRAK DEGRADERS AND USES THEREOF	IRAK2, IRAK3, IRAK1	MEN1 4055/4885KMT2A 445/4885HTT 2464/4885
US-11807636-B2	IRAK degraders and uses thereof	IRAK2, IRAK3, IRAK1	MEN1 4055/4885KMT2A 445/4885HTT 2464/4885
US-20190119222-A1	NOVEL ANTI-INFLAMMATORY AGENTS	VCAM1, ICAM1, IL6	MEN1 3913/4885KMT2A 3826/4885HTT 4528/4885
US-20120040954-A1	NOVEL ANTI-INFLAMMATORY AGENTS	VCAM1, ICAM1, IL6	MEN1 3913/4885KMT2A 3826/4885HTT 4528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.